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1. Introduction 
Crohn's disease (CD) and Ulcerative Colitis (UC) are collectively referred to as inflammatory 
bowel disease (IBD). Ulcerative Colitis was originally described in the medical journals in 
1859, but it was not until 1925 that the first case-report of a colitis-associated colorectal 
cancer (CACRC) was published by Crohn and Rosenborg (reviewed in (Greenstein, 2000)). 
Since then it has become clear that IBD ranks as a high-risk condition for the development of 
colorectal cancer (CRC), with a standardized incidence ratio of 2.4 (95% CI 0.6-6.0) in 
patients with extensive or pan UC. This risk is associated with longer disease duration, 
earlier age of onset (Ekbom et al., 1990), the greater the severity of inflammation (Rutter et 
al., 2004) and the presence of concomitant inflammatory conditions such as primary 
sclerosing cholangitis (PSC) (Claessen et al., 2009). This suggests that the acquired cancer 
risk is a consequence of the inflammatory process itself, resulting from repeated cycles of 
ulceration and epithelial regeneration. Moreover, the molecular and histopathology of 
colitis-associated colorectal cancer (CACRC) is distinct from that of sporadic colorectal 
cancer (SCRC), and understanding this is crucial to enable the development of effective 
and beneficial screening programmes for patients with long-standing ulcerative colitis 
(UC). 
2. Tumorigenesis of colon cancer in ulcerative colitis 
2.1 Stem cells, inflammation and field cancerisation 
It is generally thought that most cancers arise as a result of a single, mutated stem cell, as 
these are the only cells that have sufficient life span to acquire the multiple oncogenic 
mutations required for tumorigenesis. There is now good evidence to support this in mice. 
Deletion of Apc in the intestinal stem cells resulted in large numbers of intestinal macro-
adenomas; however when Apc was deleted in non-stem cells, adenomas were significantly 
fewer and only able to reach a very small size (Barker et al., 2009). In this section the 
processes by which the progeny of a mutated stem cell can come to form a dysplastic lesion 
and the pro-oncogenic effects of chronic inflammation will be summarised. 
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2.1.1 Inflammation and the stem cell niche 
Inflammatory bowel disease is characterised by the presence of an inflammatory mucosal 
infiltrate. Infiltrating leucocytes and activated mesenchymal myofibroblasts secrete a large 
number of pro-inflammatory cytokines, growth factors and morphogens that can all have 
profound effects on the stem cell niche. At present there is little evidence for a direct effect of 
inflammation on the mammalian intestinal stem cell niche however this is a research area of 
great interest. A recent study by Ren et al (Ren et al., 2010) in Drosophila intestine 
demonstrated that the evolutionary conserved Hippo (Hpo) signalling pathway is important 
for regulating intestinal stem cell proliferation and survival, and that dysregulation of this 
pathway with increased stem cell proliferation occurs with mucosal inflammation. 
Importantly disruption of the Hpo pathway has been associated with a number of human 
cancers, thus suggesting one possible mechanism whereby inflammation may be driving 
tumorigenesis in IBD through a direct effect on the stem cell niche. 
2.1.2 Crypt fission and clonal expansion 
In order to understand how a single, mutated stem cell can result in a cancer we need to 
look at the dynamics of the normal colonic crypt. There are thought to be a small number of 
clonally related stem cells located at the base of each crypt within a niche (Williams et al., 
1992; Campbell et al., 1996; Yatabe et al., 2001; Barker et al., 2007). The number of stem cells 
within the niche is tightly controlled. However with random loss or gain of stem cells from 
the niche, a single stem cell and its progeny can stochastically expand within the niche until 
all the stem cells within the niche are derived from the same lineage (Yatabe et al., 2001) – 
this process is termed niche succession (Figure 1). In the normal human crypt this is thought 
to be a slow process, with successive niche succession cycles occurring around every 8-9 
years (Humphries & Wright, 2008; Graham et al., 2011). As a consequence of the niche 
succession process the progeny of that stem cell lineage will then take over the whole crypt, 
and this is termed monoclonal conversion (Figure 1). In order for the normal gut to grow 
during childhood or to replace crypts that die, often as a result of inflammation – epithelial 
restitution, there has to be a mechanism for crypts to expand, and this is achieved via the 
process of crypt fission whereby a single parent crypt divides to form two daughter crypts 
(Figure 1). Although all these processes are slow in the normal colon, they have the potential 
to be up-regulated, either due to inflammation or an oncogenic mutation arising in a stem 
cell, and it is by the process of crypt fission that mutated crypts are then able to expand and 
grow within the epithelium to form a dysplastic lesion (Park et al., 1995; Wong et al., 2002; 
Greaves et al., 2006 ; Humphries & Wright 2008). 
We have discussed the processes of niche succession and monoclonal conversion as inherent 
properties of the stem cell niche. Now imagine that a stem cell gains a selective advantage, 
potentially an oncogenic mutation induced by the dysregulation of normal inhibitory 
pathways of stem cell proliferation due to chronic inflammation, then the process of niche 
succession and clonal conversion will take place rapidly with the result mutant cells 
occupying the whole crypt. The mutant clone is then able to expand further within the 
epithelium by crypt fission, perhaps gaining further mutations as it grows. Niche succession 
and crypt fission are likely to be the initial mechanisms behind clonal expansion in CACRC. 
Crypt fission has been shown to be responsible for the expansion spread of individual 
crypts in the colon (Greaves et al., 2006), small intestine (Gutierrez-Gonzales et al., 2009) and 
stomach (McDonald et al., 2008), and this process is a histological feature of colitis and 
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dysplasia (Park et al., 1995; Wong et al., 2002). Chen et al (Chen et al., 2005) used a 
fluorescent in-situ hybridisation technique to demonstrate the spread of TP53 mutations into 
the daughter crypts of a crypt in the process of fission in UC. 
 
 
Fig. 1. Expansion of a mutated stem cell within the colonic crypt and epithelium 
(A): a stem cell (highlighted in red) within the niche is able to expand within the niche via 
niche succession (i-iii), subsequently all the progeny of that stem cell lineage take over the 
crypt – monoclonal conversion (iv). If the stem cell has gained a selective advantage via an 
oncogenic mutation, then this can happen rapidly. (B): The mutated crypt (i) then clonally 
expands within the epithelium by dividing from the bottom up to produce two daughter 
crypts – crypt fission (ii) 
2.2 The carcinogenesis pathway in CACRC is distinct to that of SCRC 
There is accumulating histopathological, genetic and functional evidence to suggest that 
SCRC and CACRC are separate diseases. Clinically the two conditions have a number of 
distinguishing features: CACRC arises in a younger population, often from flat, not 
polypoid dysplasia and has a more proximal distribution, there is a greater frequency of 
mucinous or signet cell histology, and a higher incidence of multiple synchronous lesions in 
CACRC (Itzkowitz & Yio, 2004). From a histological perspective, sporadic tumours tend to 
follow the adenoma-carcinoma sequence. The stepwise accumulation of genetic mutations 
in onco- and tumour suppressor genes that underpins this histological progression is well 
established and has significantly altered worldwide clinical practice (Vogelstein et al., 1988). 
However CACRC progresses through low (LGD) and high-grade dysplasia (HGD) to 
carcinoma, and this carcinogenesis pathway is less well explored with significantly 
differences in the requirement and timing of genetic and epigenetic alterations (Figure 2). 
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Fig. 2. Comparison of CACRC and SCRC carcinogenesis pathways 
Both types of cancer show multi-step development with sequential mutation in tumour 
suppressor and oncogenes. The main difference between the pathways is in the timing of 
these mutations: APC is the initiating mutation in almost all SCRC, but is rarely found in 
CACRC and when present often occurs late in tumour development. Abbreviations: APC, 
Adenomatous polyposis coli; DCC, deleted in colon cancer; K-RAS, Kirsten-Ras; LOH, loss 
of heterozygosity; MSI, microsatellite instability. 
2.2.1 Canonical Wnt signalling in SCRC and CACRC 
Wnts are a large family of secreted glycoproteins with at least 19 known human members 
that are expressed in species ranging from Drosophila to man. Wnt signalling plays a critical 
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role in the development and homeostasis of the intestinal epithelium, having a central role 
in maintenance of the stem cell phenotype, control of epithelial cell proliferation and 
localisation, secretory lineage development and the maturation of Paneth cells (reviewed in 
(Scoville et al., 2008)). As the main proliferative drive, Wnt signalling is also believed to play 
a crucial role in the regeneration of the intestinal epithelium following damage. The 
Adenomatous Polyposis Coli (APC) protein is a component of the canonical Wnt pathway 
and is responsible for the regulation of the transcription factor β-catenin. In the absence of 
canonical Wnt ligand the APC destruction complex phosphorylates the N-terminal of β-
catenin, targeting it for ubiquitin-proteosome mediated destruction. Truncation or loss of 
APC disrupts the β-catenin degradation complex and nuclear translocation of the stabilised 
β-catenin causes increased expression of Wnt target genes (reviewed in (Sieber et al., 2000)). 
Somatic APC mutation is the initiating, gate-keeping lesion in sporadic colorectal 
carcinogenesis (Kinzler and Vogelstein 1996), and is found in 60% of sporadic adenomas 
(Powell et al., 1992) and 80% of carcinomas (Miyoshi et al., 1992), many of which show 
abnormal beta catenin expression on immunohistochemical staining (Preston et al., 2003). In 
contrast, APC mutations are rare in CACRC, occurring at a frequency of just 3-6% in the 
biggest studies  (Tarmin et al., 1995; Aust et al., 2002) (Figure 2).  
2.2.2 Epithelial restitution and alternative activation of the Wnt pathway 
Activation of the Wnt pathway by APC or β-catenin mutation is uncommon in CACRC, yet 
Wnt signalling has a key role in the control of epithelial proliferation and is up-regulated in 
epithelial restitution with increased expression of ligands and Wnt target genes such as C-
MYC in regenerating epithelium (You et al., 2008). Furthermore in mouse models, activation 
of the Wnt pathway using R-spondin (Zhao et al., 2007), or knock-out of the Wnt antagonist 
Dkk-1 (Koch et al., 2011) can prevent the initiation and improve the recovery from DSS-
induced colitis. Recent work by Lee et al (Lee et al., 2010) proposes that an alternative, 
inflammation-induced mechanism of β-catenin stabilisation may be responsible for this Wnt 
activation in colitis. They demonstrated that the PI3 Kinase /Akt pathway phosphorylates β-
catenin at a specific moiety - serine 552. Whereas N-terminal phosphorylation by the APC 
destruction complex triggers proteosome mediated destruction, PI3K phosphorylation of 
this specific amino acid does the opposite, causing nuclear translocation and target gene 
activation. This mechanism effectively bypasses the destruction complex and explains why 
APC mutation is rarely selected for in CACRC (Figure 3). 
Although Wnt signalling may be essential to induce intestinal regeneration in the short 
term, longstanding inflammation-induced Wnt activation is mitogenic (Kim et al., 2005) and 
Ashton et al (Ashton et al., 2010) have recently demonstrated one mechanism that illustrates 
how closely the inflammation and carcinogenesis pathways are entwined. They used mouse 
models to conditionally delete the downstream c-Myc target focal adhesion kinase (FAK), 
and found that these animals were unable to regenerate the intestine following tissue 
damage. However, when FAK was deleted within the adult intestine this abrogated tumour 
formation caused by Apc loss, mainly mediated by a reduction in phospho-Akt levels. This 
suggests that FAK is required downstream of Wnt signalling and upstream of 
P13K/Akt/mTor activation, mediating both intestinal regeneration and neoplastic 
transformation following Apc loss. It is these potential feedback loops between Wnt target 
genes and PI3K-mediated Wnt activation that may be responsible for driving tumorigenesis 
in chronic intestinal inflammation (Figure 3). 
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Fig. 3. Wnt activation via APC dependent and alternative inflammation induced 
mechanisms 
In sporadic tumours inactivation of APC or stabilisation of β-catenin occurs by mutation 
(flashes) inhibiting the destruction complex from N-terminal phosphorylation of β-catenin 
(P-β-catenin at amino acids 33, 37 and 41) and preventing proteosome mediated breakdown. 
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However in acute inflammation, PI3K/Akt mediated phosphorylation of serine residue 552 
(P-β-catenin at 552) causes nuclear translocation of beta catenin and target gene activation. 
Downstream of upregulated wnt target genes such as c-Myc, focal adhesion kinase (FAK) is 
involved in mediating both crypt regeneration and neoplastic transformation. Additionally 
FAK also activates P13K and this cycle of P13K/Wnt cross-talk may be involved in 
neoplastic transformation in longstanding colitis. 
2.2.3 Genetic instability in CACRC carcinogenesis 
It is now becoming clear that the inflammation and restitution processes that underlay 
chronic inflammatory bowel disease drive CACRC down alternative carcinogenesis 
pathways to their sporadic counterparts. In SCRC carcinogenesis, chromosomal instability 
leading to aneuploidy, detectable by both image and flow cytometry, is rare in established 
precursor lesions before the development of high-grade dysplasia or cancer (Sieber et al., 
2002). Yet in ulcerative colitis chromosomal instability (CIN) can be detected in 
histologically non-dysplastic tissue from high-risk patients by comparative genomic 
hybridisation (Willenbucher et al., 1997; Rabinovitch et al., 1999) and image or flow 
cytometry (Keller et al., 2001). These chromosomal abnormalities are diverse and generally 
found at low-levels (<10% of sampled cells) in pre-dysplastic biopsy samples, suggesting 
they are pre-clonal chromosomal alterations that are infrequent, random and pre-date 
clonal expansion (Bronner et al., 2008). It has been suggested that CIN occurs as a 
consequence of the effect of inflammation and reactive oxygen species encouraging 
telomere shortening, so permitting chromosomal end fusion. This results in cycles of 
chromatin bridge breakage and fusion, promoting the accumulation of chromosomal 
aberrations (O'Sullivan et al., 2002).  
Mutator phenotype or natural selection 
Chen et al. further analysed the genetic instability seen in early lesions in UC using 
arbitrarily-primed (AP-PCR) and inter-simple-sequence repeat PCR (ISSR-PCR) genetic 
fingerprinting techniques (Chen et al., 2003, 2005). The identification of DNA fingerprint 
abnormalities throughout normal and dysplastic areas of the colon allowed the subdivision 
of patients with IBD into UC progressors: patients with identifiable genomic instability who 
are likely to progress to dysplasia or cancer, and UC non-progressors: patients with normal 
DNA fingerprints who are unlikely to progress. The authors proposed that this colon-wide 
genomic instability in UC progressors provides a field from which dysplasia develops, and 
is evidence of a mutator phenotype. This theory proposes that the initiating mutation arises in 
one of the genes that maintain genetic stability, leading to an increased mutation rate and 
resulting in a heterogeneous collection of cells with the only shared mutation in the gene 
ensuring DNA fidelity (Loeb & Loeb, 1999; Chen et al., 2005). However recent experimental 
data involving detailed examination of areas of dysplasia in UC does not support this 
hypothesis.  Laser dissection and genetic analysis of individual crypts across colitis 
associated dysplasia and tumours showed that these lesions can be readily identified as 
clonal, with a shared initiating tumour suppressor or oncogene mutation demonstrated in 
each case (Leedham et al., 2009). Thus CACRC appears to follow the somatic mutation 
theory of carcinogenesis, where initial mutations in key target genes introduce a selective 
growth advantage to a cell and then the forces of natural selection and evolution act to 
expand this clone — a so called selective sweep (Maley et al., 2004). When a mutation has 
spread through an entire population it is said to have gone to fixation, as there are no longer 
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any competing alleles. Further mutations within this clone can then expand producing 
regional selective sweeps and clonal diversity.  
Clonal ordering studies utilise the spatial distribution of shared mutations throughout 
different areas of dysplasia and cancer to make inferences about the timing of mutations and 
selective sweeps. A recent clonal ordering study of colitis-associated lesions identified TP53 
as the most common single founding mutation, with K-RAS mutations the only other 
detected unique gate-keeping mutation (Leedham et al., 2009). TP53 mutation is commonly 
seen in colitis-associated lesions, with the frequency of both point mutations and 17qLOH 
correlating with malignant progression (Burmer et al., 1992; Brentnall et al., 1994; Hussain et 
al., 2000). From an evolutionary perspective the high frequency of initiating TP53 mutations 
in colitis is not surprising. With chromosomal instability arising in chronically inflamed pre-
dysplastic tissues there would be a strong selective pressure for TP53 mutation as 
inactivation of this protein would disrupt mitotic checkpoints and permit the survival of 
stem-cells with gross chromosomal changes. 
Clonal expansion and field cancerisation 
Slaughter et al. (Slaughter et al., 1953) originally proposed the term field cancerisation to 
explain the presence of multifocal head and neck cancers developing out of a field of 
precancerous change that had developed as a consequence of carcinogen exposure. The 
theory was further expanded by Braakhuis et al (Braakhuis et al., 2003), who proposed that 
the field was in fact a clonally-expanded area of mutated cells. Clonally-expanded mutated 
patches have been noted in dysplastic (Lyda et al., 1998, 2000) and phenotypically normal 
mucosa of colitis patients (Chaubert et al., 1994).  Using individual crypt genetic analysis 
Leedham et al (Leedham et al, 2009) were able to demonstrate the presence of oncogenic 
mutations in non-dysplastic crypts surrounding clonal neoplastic lesions, suggesting that 
the tumours had arisen from a field of genetically mutant yet non-dysplastic crypts. The 
presence of tumorigenic mutations in areas of morphologically non-dysplastic mucosa has 
significant clinical implications as at the present time the histological detection of dysplasia 
is the gold standard biomarker of disease progression in UC. Although endoscopic resection 
of visible dysplastic lesions may prevent tumour progression in that lesion, this work 
suggest that fields of clonally expanded genetically mutant, but non-dysplastic, crypts may 
well be left behind. 
2.2.4 DNA methylation 
CpG island hypermethylation often starts in normal mucosa as a function of age and is 
markedly increased in cancer (Issa et al., 2001). Such silencing is clonal and thought to be 
physiologically irreversible in somatic cells. Neoplastic cells often display aberrant promoter 
region methylation with epigenetic silencing of multiple genes including genes that regulate 
critical processes such as cell cycle control, DNA repair, and angiogenesis. In the colon, CpG 
islands methylated in cancer have been divided into two groups: those that display cancer-
restricted methylation (type C), and those that are methylated initially in aging normal 
epithelial cells (type A). It has been proposed that age-related methylation contributes to an 
acquired predisposition to colorectal neoplasia because methylation alters the physiology of 
aging cells and tissues (Issa et al., 2001).  This hypothesis predicts that higher levels of age-
related methylation are associated with a heightened susceptibility to developing colorectal 
cancer, and it may be present in conditions of rapid cell turnover that mimic premature 
aging such as IBD. 
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Issa et al (Issa et al., 2001), investigated the methylation status of 4 genes in patients with UC 
versus controls (ER, MYOD1, CSPG2 and p16). All four genes were highly methylated in 
dysplastic epithelium from patients with colitis-associated HGD or cancer. In addition, three 
of the four genes (ER, MYOD and p16) were also highly methylated in the normal appearing 
(non-dysplastic) epithelium from these same HGD/cancer patients, indicating that 
methylation precedes dysplasia and is widespread in these patients. These results are 
consistent with the hypothesis that age-related methylation marks (and may lead to) the 
field defect that reflects acquired predisposition to colorectal neoplasia. More recently, 
Kukitsu et al (Kukitsu et al., 2008) identified hypermethylation and subsequent reduced p16 
gene expression in aberrant crypt foci (ACF) in UC. These are the earliest detectable lesions 
in the CACRC pathway and suggest that aberrant methylation of tumour suppressor genes 
may also be an early event in CACRC carcinogenesis 
3. Who, when and how to screen? 
3.1 Who to screen 
Patients with colitis are overall thought to be at increased risk of colorectal cancer compared 
to the general population, which has lead to the development of colonoscopic surveillance 
programmes. There is no randomised data to confirm that such programmes are effective 
either in lives saved, cancer prevented or that they are cost effective. However, there is case-
control data suggesting that those in surveillance programmes have cancer detected at an 
earlier stage and are less likely to die from their cancer (Loftus, 2003; Collins et al., 2006; 
Lutgens et al., 2009). 
The level of risk of colorectal cancer in colitis had recently been questioned: a meta-analysis 
from 2001 (Eaden et al., 2001) suggested that the risk might be as high as 20% at 20 years of 
disease. However more recent analyses have suggested the risk may much lower: Rutter at 
al (Rutter et al., 2006) analysed prospectively collected data from six-hundred patients 
collected over a thirty-year period and found that the CRC risk by colitis duration was 2.5% 
at 20 years, 7.6% at 30 years, and 10.8% at 40 years. This may reflect a higher risk seen in 
studies based in referral centres compared to true population-based estimates. Disease 
extent is also important, with extensive disease conferring the highest risk and proctitis 
generally being regarded as harbouring no increased risk (Ekbom et al., 1990). Indeed, in the 
Olmstead county population based study from Minnesota USA (Jess et al., 2006), only 
patients with extensive colitis were seen to be at increased risk of colorectal cancer. 
Other significant risk factors, apart from disease extent, include primary sclerosing 
cholangitis (even after liver transplant) (Broome et al., 1995; Claessen et al., 2009), a family 
history of colorectal cancer (Askling et al., 2001), persistent mucosal inflammation (Rutter et 
al., 2004), strictures, post-inflammatory polyps (Rutter, Saunders et al. 2004) and previous 
dysplasia. Conversely, patients with no endoscopic or histological evidence of inflammation 
- mucosal healing - have the same 5-year risk of CRC as the background, non-UC population 
(Rutter et al., 2004). This recognition that not all patients have the same level of risk has led 
some guideline writers to move to a surveillance model based on risk stratification, rather 
than by disease duration as had been done previously. This has been adopted most clearly 
in the new British Society of Gastroenterology Guidelines 2010 (Cairns et al., 2010) (Figure 
3), with very similar UK guidance released for the National Institute for Clinical Excellence 
in 2011 (NICE, 2011), with those at highest risk now being offered yearly surveillance, and 
those at lowest risk 5-yearly interval surveillance. 
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3.2 When to start screening 
Most guidelines recommend starting screening at 8-10 years of disease duration (N.B. not 
from diagnosis, but from when symptoms started). This is based on the relatively low cancer 
rates seen within 10 years of disease initiation, particularly with population-based estimates, 
and is consistent with long-term inflammation driving the increased cancer risk in colitis. 
Nevertheless, some studies have reported relatively high rates of cancer within the 1st 
decade of disease (Lutgens et al., 2008). However most studies show that the incidence of 
CRC is low in the first decade (Eadens et al., 2001; Jess et al., 2006; Rutter et al., 2006), and 
therefore commencing surveillance prior to 8-10 years increases the cost of surveillance 
programmes with little added benefit. 
 
 
Fig. 4. Updated endoscopic surveillance recommendations from the British Society of 
Gastroenterology (Cairns et al., 2010) 
Patients are now statified according to low, intermediate and high risk risk and advised to 
undergo 5-yearly, 3-yearly or yearly colonoscopic screening respectively. 
3.3 How to screen 
3.3.1 Endoscopic screening 
Recent guidelines from the United Kingdom and Europe have endorsed the use of 
chromoendoscopy to enhance dysplasia detection, on the basis of single-centre randomised 
trials, back-to-back studies and case-control data (see Table 1). This is a paradigm shift away 
from previous strategies that relied upon large numbers of random biopsies (33 or more) to 
detect invisible or flat dysplasia. Recent evidence suggest that much, if not most, dysplasia in 
colitis is detectable with white light endoscopy (Rutter et al., 2004), probably reflecting 
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better endoscope optics (high resolution instruments) and improved operator experience in 
detecting subtle, flat lesions. Detection can be further enhanced by the use of 
chromoendoscopy dye-spray, where dye is sprayed onto the bowel epithelium to highlight 
subtle mucosal abnormalities; the use of dye-spray increases dysplasia detection by 2-3 fold 
on a per patient basis, and 4-5 fold on a per lesion basis. However, it remains unclear 
whether dysplasia detected with dye-spray has the same natural history as that detected 
with white light endoscopy and multiple random biopsy strategy. Other advanced imaging 
techniques such as auto-fluorescence endoscopy, narrowed spectrum endoscopy (NBI, 
FICE, i-Scan), and confocal endomicroscopy remain research based and are not endorsed in 
any international guideline at present. 
 
 
Table 1. Summary of trials of chromo-endoscopy in UC surveillance 
Proportion of patients with at least one dysplastic lesion detected is denoted in brackets. 
Chromo-endoscopic techniques significantly increase detection of dysplasia in UC screening 
colonoscopy 
3.3.2 Molecular techniques and biomarkers for progression to neoplasia 
Biopsies from screening colonoscopies of patients with UC are still routinely processed and 
only basic histological techniques used to look for evidence of dysplasia or cancer. The 
interpretation of biopsies in the presence of active inflammation is difficult, therefore 
combining basic histology with analysis of the molecular pathology or protein expression 
could enable improved detection of dysplasia. Moreover, a significant proportion of patients 
with low-grade dysplasia or who are indefinite for dysplasia (ID) do not progress to 
neoplasia, therefore there is a need for biomarkers that can accurately differentiate the non-
progressors from the progressors who require intensive surveillance or more aggressive 
management. Although there has been much focus from various groups on developing 
simple techniques that can complement standard histology, these are yet to be translated to 
everyday clinical practice. 
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As previously discussed, for over 20 years image cytometry looking for evidence of 
aneuploidy in biopsy samples has been shown to correlate with dysplasia and identify a 
sub-group of patients at higher risk of developing dysplasia and cancer (Lofberg et al., 1992; 
Rubin et al., 1992; Keller et al., 2001) – UC progressors.  It is known that patients with UC 
harbour TP53 mutations in non-dysplastic mucosa and this may confer susceptibility to the 
development of CRC (Hussain et al., 2000; Leedham et al., 2009), therefore this offers 
another potential way of identifying those patients at high risk of CRC that may need 
intensive endoscopic screening. Immunohistochemical staining of tissue for TP53 and 
Alpha-methylacyl-CoA racemase (AMACR) - an enzyme involved in fatty acid metabolism 
that has known altered expression in various cancers including CRC – has recently been 
shown to be a potential marker for progression to HGD and neoplasia in UC (van Schaik et 
al., 2011). Using comparative and quantitative proteomics, panels of proteins that are 
differentially expressed in the dysplastic and non-dysplastic mucosa of UC progressors and 
non-progressors have been identified (Bronner et al., 2010; May et al., 2011). Specifically 
S100P - a calcium binding protein, TRAP1 - a mitochondrial heat-shock protein, and CPS1 - 
a mitochondrial protein involved in urea metabolism, have all been shown to be 
significantly over-expressed by immunohistochemical staining in both the dysplastic and 
non-dysplastic (rectal) tissue of UC progressors compared to non-progressors. 
Immunohistochemistry for rectal CPS1 was able to predict dysplasia or cancer in the colon 
with 87% sensitivity and 45% specificity (May et al., 2011). 
Genomic biomarkers offer perhaps the most promising molecular tool for screening UC 
patients: Studies have demonstrated that genomic instability can be detected throughout the 
colon of patients with UC, importantly genomic instability detected in non-dysplastic rectal 
biopsies, using FISH or array based comparative genomic hybridisation, is able to 
differentiate UC progressors from non-progressors with a high sensitivity and specificity 
(Bronner et al., 2008, 2010).  
Biomarkers appear to offer the potential to identify those high-risk patients that require 
colonoscopic screening on only a few rectal biopsies. However, it remains to be seen 
whether larger studies confirm this and if an affordable, simple, reproducible and reliable 
technique can be developed for standard clinical use.  
3.4 Management of dysplasia in UC 
The aim of screening is to detect dysplasia that can then be removed, either endoscopically 
or by colectomy depending on the type of lesion and histological grade, in order to prevent 
the development of cancer. The more specific, surgical aspects of how to manage patients 
once dysplasia has been detected are covered in a separate chapter. 
There has been a recent significant practice shift in the management of dysplasia and 
dysplastic polyps when detected in the colon of patients with UC, with the recent 
publication of guidelines from the United Kingdom, Europe and the United States (Travis et 
al., 2008; Cairns et al., 2010; Farraye et al., 2010; NICE, 2011) all advocating a similar, more 
conservative approach. Where a dysplastic polyp arises in an area proximal to the extent of 
the colitis, with no evidence of dysplasia in the surrounding flat mucosa, it can be treated in 
the same way as a sporadic adenoma, usually with complete endoscopic resection. 
Dysplastic polyps arising in an area of inflammation have been termed dysplasia-associated 
lesions or masses (DALMs). More recently, the term adenoma-like mass (ALM) or adenoma-
like DALMs have been used to describe areas of dysplasia in the inflamed colon that more 
resemble sporadic adenomas and are thus endoscopically resectable. Previously, if an area 
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of dysplasia was detected within the inflamed colon then colectomy was felt to be 
mandatory. However, a number of studies have demonstrated that for ALM or adenoma-
like DALMs, once endoscopically resected, prognosis is good (Engelsgjerd et al., 1999; Rubin 
et al., 1999; Odze et al., 2004; Rutter et al.,2004). One such study examining 40 patients 
undergoing endoscopic resection of dysplastic polyps within inflamed mucosa reported one 
case of adenocarcinoma after a mean follow-up period of 4.1 years (Odze et al., 2004). This 
was not significantly different from the frequency of cancer within the surveillance 
population as a whole (p=1.0, Fisher ’s exact test). On the other hand, if the dysplastic polyp 
cannot be completely excised, urgent re-assessment of resectability by an experienced 
colonoscopist or urgent surgery is mandatory regardless of the grade of dysplasia. If a 
dysplastic polyp is arising within a field change of dysplastic tissue in the surrounding flat 
mucosa colectomy is advised, as complete endoscopic excision of the lesion is not achievable 
(Mowat et al., 2011). 
4. Prevention is better than cure 
4.1 Mucosal healing in UC 
The management of IBD is fast evolving, with tantalising therapeutic biological agents 
currently under review and there has been a paradigm shift in the way in which 
Gastroenterologists manage UC. Traditionally, inducing and maintaining symptom control 
was the focal aim, however mucosal healing is now a key endpoint in the management of 
IBD. Mucosal healing is defined as the absence of all mucosal ulceration, both macroscopic 
and microscopic, providing a sigmoidoscopy score of 0, as assessed by the Ulcerative Colitis 
Disease Activity Index. As previously discussed, severity of inflammation, more extensive 
disease and longer duration of disease have all been demonstrated to increase the overall 
risk of CRC (Ekbom et al., 1990; Eaden et al., 2001; Rutter et al., 2004; Bielas et al., 2006; Jess 
et al., 2006; Rutter et al., 2006). Consequently, mucosal inflammation is clearly associated in 
CRC development and tailoring treatments towards mucosal healing should, therefore, 
curtail the risk of CRC development. However serious infections, malignancies – namely 
lymphomas - and neurological disease all complicate current anti-TNF treatments and long-
term immunosuppression in IBD patients (Lees et al., 2009). Long-term follow up data is 
lacking, especially for combination therapies, but it appears that thiopurines are associated 
with a 3-5 fold increase in lymphoma risk and there is as much as a 3-fold increased relative 
risk for anti-TNF therapies (Bewtra & Lewis 2010). Although the absolute risks are low, 
careful consideration needs to be given when using these therapies and patients require 
close monitoring and follow up. As long-term studies become available we will be better 
equipped to assess the chemo-preventative benefits of immunomodulator induced mucosal 
healing versus the small risks of lymphoproliferative cancer induction. 
4.2 Chemo-prevention in UC 
4.2.1 5-ASAs 
An important aspect of the use of 5-ASAs is not only in the induction and maintenance of 
remission, but also in the prevention of colonic dysplasia and CRC. Their efficacy may be 
only partially explained by anti-inflammatory effects, as other more potent anti-
inflammatory agents, such as glucocorticoids and azathioprine, have a lower cancer 
protective effect. Further chemo-preventative effects of 5-ASA compounds are thought to 
comprise modulation of inflammatory cytokine production (Foutch & Zimmerman 1996), 
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inhibition of cyclo-oxygenase (Allgayer, 2003), inducible NO synthase (Kennedy et al., 1999; 
Hasko et al., 2001) and nuclear factor KB (Wahl et al., 1998; Greten et al., 2004), as well as 
activation of peroxisome proliferator activated receptor (PPAR) gamma (Rousseaux et al., 
2005; Dubuquoy et al., 2006). In addition, 5-ASA’s scavenge oxygen free radicals, have an 
antimicrobial action and are capable of inhibiting protein phosphatase 2A – which, in turn, 
can curtail Wnt pathway activity (van Rijn et al., 2006). Despite the notion that these 
processes could be chemo-preventative, there are no prospective randomised controlled 
trials to substantiate the protective effect of 5-ASA in cancer chemoprevention in colitis. The 
most impressive evidence to support their use comes from the meta-analysis by Velayos et 
al (Rubin et al., 2008): this study showed a significantly reduced risk of the development of 
cancer or dysplasia in UC patients on long-term 5-ASA treatment, with a pooled odds ratio 
of 0.51 (95% CI 0.38- 0.69). 
4.2.2 Folic acid 
It is hypothesised that folic acid deficiency can induce DNA hypomethylation and thus 
dysregulated expression of oncogenes (Duthie 1999). There are a number of long-term 
observational studies that demonstrate a significant reduction in colorectal adenoma and 
cancer rates in patients taking folate supplements (Giovannucci et al., 1998; Terry et al., 
2002). However no studies specifically looking at ulcerative colitis or IBD have been 
undertaken, and a more recent study found no protective effect of folic acid on colorectal 
adenoma recurrence (Logan et al., 2008). 
4.2.3 Ursodeoxycholic acid  
Patients with ulcerative colitis and PSC have significantly increased risks of colorectal 
cancer (Claessen et al., 2009), and treatment with the synthetic bile acid ursodeoxycholic 
acid has been advocated to treat complications of liver disease in both PSC and other 
cholestatic liver conditions, however its exact mechanism of action is unclear. There is 
evidence that the secondary bile acid, deoxycholic acid, promotes colorectal carcinogenesis:  
Patients with ulcerative colitis and colonic dysplasia or carcinoma have higher faecal bile 
acid concentrations than do patients with ulcerative colitis but without colonic neoplasia 
(Hill et al., 1987), and serum levels of deoxycholic acid, which in a steady state are assumed 
to reflect the amount of deoxycholic acid absorbed from the colon, have also been found to 
be significantly elevated in men with colonic adenomas compared with controls 
(Bayerdorffer et al., 1993; Bayerdorffer et al., 1995). A prospective, randomised control trial 
of ursodeoxycholic acid in patients with ulcerative colitis and PSC, demonstrated 
significantly lower rates of colorectal dysplasia and cancer in the treatment group, with an 
odds ratio of 0.26 (95% CI, 0.06–0.92; P < 0.03) (Pardi et al., 2003).  However other studies 
have not confirmed this observed reduction (Wolf et al., 2005), and a recent long-term study 
of patients with UC and PSC taking high dose ursodeoxycholic acid reported an increased 
rate of colorectal neoplasia (Eaton et al., 2011). Thus this is a controversial area and long-
term ursodeoxycholic acid cannot currently be recommended as chemoprevention in 
patients with ulcerative colitis (Chapman et al., 2010). 
4.3 NSAIDs and aspirin chemoprevention of CRC 
It is generally thought that carcinogenesis seems to arise as a result of accumulations of 
genetic and epigenetic modifications in tissue stem cells or progenitors which are 
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pluripotent and capable of self-renewal (Humphries & Wright 2008). A recent study has 
suggested that NSAIDS are able to provide effective chemoprevention of CRC by targeting 
stem cells that have accumulated pro-tumorigenic mutations, and can eliminate them by the 
induction of apoptosis (Qiu et al., 2010). In an Apc Min/+ mouse model, dietary sulindac, (an 
NSAID), induced apoptosis in intestinal stem cells with nuclear or phosphorylated β-
catenin. Not only that, in human colonic polyps, NSAIDS were shown to induce apoptosis 
in cells with aberrant Wnt signalling. The tumour-suppressive effect of sulindac in the Apc 
Min/+ mouse model was reduced by a deficiency in mitochondrial apoptogenic protein, 
SMAC. It blocked apoptosis and removal of stem cells with nuclear or phosphorylated β-
catenin. This is an exciting prospect for the use of chemical agents or simple dietary changes 
as anti-cancer therapies in the future. 
Studies have demonstrated that the use of aspirin (Baron et al., 2003; Benamouzig et al., 
2003; Logan et al., 2008; Cole et al., 2009) and cyclo-oxygenase-2 enzyme (COX-2) inhibitors 
(Bertagnolli et al., 2006; Arber et al., 2006; Baron et al., 2003) is associated with a 20% 
reduction in adenoma recurrence, the precursor lesion of most SCRC. However, certain 
COX-2 inhibitors were taken off the market by the Food and Drug Administration (FDA), in 
2004, following several landmark studies showing an increased risk of stroke and 
myocardial infarction (Kerr et al., 2007) and are thus no longer able to be considered as 
preventative treatments. Aspirin is still a contender for usage as long-term 
chemoprevention. A recent meta-analysis pooling long-term follow up data from four 
randomized, double-blind, placebo-controlled trials of aspirin treatment (Rothwell et al., 
2010), demonstrated that regular low dose (75mg) aspirin reduced long-term risk of colon 
cancer  - its overt effect taking 7-8 years; (incidence hazard ratio [HR] 0.76, 95% CI 0.60-0.96, 
p=0.02; mortality HR 0.65, 0.48-0.88, p=0.005). The median follow follow up was over 18 
years. Aspirin doses less than 30mg were less effective than 75mg and greater than 75mg 
conferred no further advantage. Furthermore, aspirin 75mg reduced cancer risk in the 
proximal colon by 5%. This was not demonstrated in the distal colon. In addition, 5-year 
maintenance treatment with aspirin resulted in a 70% decrease in the consequent risk of 
proximal colon cancer (Rothwell et al., 2010).  However, one of several limitations in this 
study was that CRC was not the primary outcome in any of the included trials. 
Furthermore, overall mortality was not reported upon, nor was the mortality related to 
aspirin side effects. What is more, the trials mostly involved men with cardiovascular risk. 
The underlying CRC carcinogenesis process may vary between patients, particularly those 
with cardiovascular risk factors. Eberhart et al, (Eberhart et al., 1994) published a 
prospective cohort study of 1279 patients, and demonstrated that after CRC diagnosis, 
exclusively in patients who’s cancers over expressed COX-2, routine aspirin usage was 
associated with a decreased cancer-specific and overall mortality.  
Although these studies do not specifically look at CRC risk in patients with UC, a previous 
case-control study (Bansal & Sonnenberg 1996) did demonstrate a protective effect of NSAID 
in IBD patients similar to that in patients without IBD. However, in the absence of prospective, 
randomized controlled data the potential side effects of long term aspirin or NSAIDs in IBD 
patients mean their use as chemo-preventative agents cannot currently be advocated. 
5. Conclusions 
In this chapter the origins of dysplasia in CACRC have been summarised and the key 
contrasts to tumorigenesis in SCRC highlighted. UC involves chronic inflammation of the 
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bowel mucosa, so it is logical to think that this is the key mechanism that drives 
carcinogenesis in these patients. The carcinogenic effect of chronic inflammation is multi-
factorial, directly affecting the stem cell niche as well as altering key signalling pathways 
and promoting genetic and epigenetic instability. Here we have demonstrated how a 
mutated stem cell can become fixed within a colonic crypt and then drive the progression 
and clonal expansion of that mutated crypt to form a dysplastic lesion. In SCRC mutations 
in APC are the initial oncognenic change that enables the growth of most adenomas. 
However, in IBD, dysplasia develops on the background of a field of mutated crypts that 
have clonally expanded over a significant area of the epithelium, but may appear 
histologically normal, with mutations in the tumour suppressor TP53 and the KRAS 
oncogene occurring early in the carcinogenesis pathway.  Chromosomal instability is 
another key early event in the progression to dysplasia in IBD patients, and there is much 
evidence to suggest that this is a pan-colonic event that precedes dysplasia. Thus dysplasia 
and cancer in UC may arise from a process of CIN that affects the entire colon, some of these 
changes select for loss of tumour suppressor genes with subsequent clonal expansion, field 
cancerisation and evolution to cancer. 
In order to improve outcomes of patients with IBD it is now apparent that suppressing 
chronic inflammation is crucial. As goals of treatment become more aggressive - aimed at 
mucosal healing rather than just symptom control, and more effective medical treatments 
become available, we may well see a drop in the colorectal cancer rates over time. An 
understanding of the molecular pathogenesis of dysplasia and CRC in UC is now crucial for 
clinicians in order that they may effectively manage the long-term outcomes of these 
patients. Although many centres operate endoscopic screening programmes aimed at 
detecting dysplasia in high-risk patients, the evidence that they significantly alter the 
natural history of colorectal cancer is limited. Also, there appears to have been little appetite 
to improve histological detection of dysplasia by complementing standard histopathology 
with more advanced, molecular and immunohistochemical techniques that have been 
shown to correlate with histological stage progression to neoplasia. Genomic biomarkers 
and immunohistochemical staining of rectal biopsies appear to be able to distinguish UC-
progressors from non-progressors.  Therefore we may soon see a move to combined 
endoscopic and biomarker based screening programmes that are able to identify those 
patients at high risk of dysplasia that require intensive colonoscopic screening from a simple 
rectal biopsy. 
There is not yet sufficient experimental evidence for effective, safe chemo-preventative 
treatments aimed at reducing colorectal cancer risk in IBD patients. However, as our 
understanding of the detailed molecular histopathological pathways of colorectal cancer in 
inflammatory bowel disease develops, so the likelihood of identifying novel targets and 
developing regimes that can significantly reduce the incidence of CRC in ulcerative colitis 
increases.  
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